Search

Charles River Laboratories International Inc

Open

BrancheGesundheitswesen

203.05 -0.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

199.96

Max

203.85

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

56M

Verkäufe

-27M

1B

KGV

Branchendurchschnitt

592.3

78.892

EPS

2.43

Gewinnspanne

5.529

Angestellte

18,700

EBITDA

-23M

198M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-1.14% downside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.2B

10B

Vorheriger Eröffnungskurs

203.24

Vorheriger Schlusskurs

203.05

Nachrichtenstimmung

By Acuity

100%

0%

362 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Dez. 2025, 15:21 UTC

Ergebnisse

Correction to Home Depot Outlook Headline on Dec. 9

23. Dez. 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. Dez. 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Dez. 2025, 21:21 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. Dez. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara to Hold Deposit in Escrow

23. Dez. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. Dez. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. Dez. 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. Dez. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. Dez. 2025, 19:13 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. Dez. 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. Dez. 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. Dez. 2025, 17:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

23. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. Dez. 2025, 17:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. Dez. 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. Dez. 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. Dez. 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. Dez. 2025, 16:03 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Bank: Closing Expected Around Mid-January

23. Dez. 2025, 16:03 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. Dez. 2025, 16:02 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. Dez. 2025, 16:01 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Bank Receives Green Light for Acquisition in Poland

23. Dez. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. Dez. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Telefonica Doesn't Set Out Financial Details of Divestment

23. Dez. 2025, 15:41 UTC

Akquisitionen, Fusionen, Übernahmen

Telefonica: Deal Will Allow Focus on Core Markets

23. Dez. 2025, 15:40 UTC

Akquisitionen, Fusionen, Übernahmen

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. Dez. 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

-1.14% Nachteil

12-Monats-Prognose

Durchschnitt 200.55 USD  -1.14%

Hoch 225 USD

Tief 170 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

7

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

362 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat